05 Oct, 2022 Alnylam Presents at OTS 2022 Annual Meeting
Posted at 12:00h
in Capella
We presented on platform and clinical results at the Oligonucleotide Therapeutics Society (OTS) 2022 18th Annual Meeting held in Phoenix, Arizona on October 2-5, 2022.
Human Genetics as an Enabler of RNAi Therapeutics – Paul Nioi
Phase 3 study, HELIOS-A, in hATTR Patients Evaluating a Single Dose Regimen – Gabriel Robbie
Toxicology and DMPK Assessment of siRNA Therapeutics – Joe Dybowski
